A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) Conference

Lassman, Andrew, Pugh, Stephanie, Wang, Tony et al. (2019). A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) . NEURO-ONCOLOGY, 21 17-17.

Industry Collaboration International Collaboration

cited authors

  • Lassman, Andrew; Pugh, Stephanie; Wang, Tony; Aldape, Kenneth; Gan, Hui; Preusser, Matthias; Vogelbaum, Michael; Sulman, Erik; Won, Minhee; Zhang, Peixin; Moazami, Golnaz; Macsai, Marian; Gilbert, Mark; Bain, Earle; Blot, Vincent; Ansell, Peter; Samanta, Suvajit; Kundu, Madan; Seidel, Clemens; De Vos, Filip; Hsu, Sigmund; Cardona, Andres; Lombardi, Giuseppe; Bentsion, Dmitry; Peterson, Richard; Gedye, Craig; Lebrun-Frenay, Christine; Wick, Antje; Curran, Walter; Mehta, Minesh

sustainable development goals

authors

date/time interval

  • November 20, 2019 -

publication date

  • November 1, 2019

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • AZ, Phoenix

Conference

  • 24th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd SNO-SCIDOT Joint Conference on Therapeutic Delivery to the CNS

publisher

  • OXFORD UNIV PRESS INC

start page

  • 17

end page

  • 17

volume

  • 21